scispace - formally typeset
P

Paul K. Keith

Researcher at McMaster University

Publications -  97
Citations -  10167

Paul K. Keith is an academic researcher from McMaster University. The author has contributed to research in topics: Asthma & Allergy. The author has an hindex of 36, co-authored 87 publications receiving 9202 citations. Previous affiliations of Paul K. Keith include University of Rochester & McMaster University Medical Centre.

Papers
More filters
Journal ArticleDOI

Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

Jean Bousquet, +95 more
- 01 Apr 2008 - 
TL;DR: The ARIA guidelines for the management of allergic rhinitis and asthma are similar in both the 1999 ARIA workshop report and the 2008 Update as discussed by the authors, but the GRADE approach is not yet available.
Journal ArticleDOI

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema

Tom Bowen, +59 more
TL;DR: Consensus approach is only an interim guide to a complex disorder such as HAE and should be replaced as soon as possible with large phase III and IV clinical trials, meta analyses, and using data base registry validation of approaches.
Journal ArticleDOI

World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines

TL;DR: The WAO Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines was planned to provide physicians everywhere with a management tool to deal with CMA from suspicion to treatment and to relieve the burden of issues through an ongoing and collective effort of more interactive debate and integrated learning.
Journal ArticleDOI

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema

Marco Cicardi, +59 more
TL;DR: In patients with hereditary angioedema having acute attacks, a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificantbenefit of ic atibant in the other trial are found with regard to the primary end point.